Does the use of peripheral immune‐related markers indicate whether to administer pazopanib, trabectedin, or eribulin to advanced soft tissue sarcoma patients?

Eijiro Shimada, Makoto Endo, Yoshihiro Matsumoto, Kenji Tsuchihashi, Mamoru Ito, Hitoshi Kusaba, Akira Nabeshima, Tomoya Nawata, Akira Maekawa, Tomoya Matsunobu, Nokitaka Setsu, Toshifumi Fujiwara, Keiichiro Iida, Makoto Nakagawa, Takeshi Hirose, Masaya Kanahori, Ryunosuke Oyama, Taichi Isobe, Hiroshi Ariyama, Kenichi KohashiHidetaka Yamamoto, Yoshinao Oda, Yukihide Iwamoto, Koichi Akashi, Eishi Baba, Yasuharu Nakashima

研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

6 被引用数 (Scopus)

フィンガープリント

「Does the use of peripheral immune‐related markers indicate whether to administer pazopanib, trabectedin, or eribulin to advanced soft tissue sarcoma patients?」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

Pharmacology, Toxicology and Pharmaceutical Science